Organogenesis Holdings Inc.
(NASDAQ CM: ORGO)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Organogenesis Holdings Inc. ("Organogenesis") on behalf of stockholders. A class action complaint has been filed against Organogenesis, which alleges that defendants made materially false and misleading statements regarding Organogenesis's business, operations, and prospects. Specifically, the complaint alleges that: (i) Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by, among other things, setting the price for those products multiple times higher than similar products; (ii) Organogenesis improperly induced doctors to use its Affinity and PuraPly XT products through lucrative reimbursements; (iii) as a result, Organogenesis's revenue and profits derived from its Affinity and PuraPly XT products were at least in substantial part unsustainable; and (iv) accordingly, Organogenesis's public statements were materially false and misleading at all relevant times.